Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L(1)Mab-4

Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L(1)Mab-4 (IgG(2b), kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. L(1)Mab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. L(1)Mab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of L(1)Mab-4. These results indicate that L(1)Mab-4 could be useful for investigating the function of hPD-L1 in oral cancers.